JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Strona główna・Stock List・Avita Therapeutics Inc

Avita Therapeutics Inc

Closed

4.54 2.02

Buy Sell

Overview

Share price change

24h

Current

Min

4.41

Max

4.67

Key metrics
By Trading Economics
Income	1.6M -12M
Sales	554K 18M
Profit margin	-65.968
Employees	226
EBITDA	1.6M -9.7M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+41.93% upside

Dividends
By Dow Jones
Next Earnings	14 maj 2026

Market Stats
By TradingEconomics
Market Cap	30M 153M
Previous open	2.52
Previous close	4.54

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

8.83 / 9.77 Support & Resistance

Avita Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 kwi 2026, 23:15 UTC

Major News Events

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 kwi 2026, 23:08 UTC

Earnings

Major Market Movers

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 kwi 2026, 23:58 UTC

Earnings

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 kwi 2026, 23:58 UTC

Earnings

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 kwi 2026, 23:56 UTC

Earnings

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 kwi 2026, 23:56 UTC

Earnings

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 kwi 2026, 23:48 UTC

Market Talk

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 kwi 2026, 23:42 UTC

Market Talk

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 kwi 2026, 23:34 UTC

Market Talk

Major News Events

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 kwi 2026, 23:30 UTC

Market Talk

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 kwi 2026, 23:08 UTC

Market Talk

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 kwi 2026, 23:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 kwi 2026, 23:02 UTC

Market Talk

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 kwi 2026, 22:42 UTC

Market Talk

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 kwi 2026, 22:10 UTC

Earnings

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 kwi 2026, 22:09 UTC

Earnings

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 kwi 2026, 22:09 UTC

Earnings

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 kwi 2026, 22:09 UTC

Earnings

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 kwi 2026, 21:56 UTC

Earnings

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 kwi 2026, 21:55 UTC

Earnings

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 kwi 2026, 21:55 UTC

Earnings

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 kwi 2026, 21:44 UTC

Earnings

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 kwi 2026, 21:43 UTC

Earnings

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 kwi 2026, 21:41 UTC

Earnings

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 kwi 2026, 21:41 UTC

Earnings

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 kwi 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

27 kwi 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

27 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27 kwi 2026, 20:39 UTC

Earnings

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Peer Comparison

Price change

Avita Therapeutics Inc Forecast

Price Target

By TipRanks

41.93% upside

12 Months Forecast

Average 6.33 USD 41.93%

High 10 USD

Low 3.5 USD

Based on 4 Wall Street analysts offering 12 month price targets forAvita Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Avita Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

8.83 / 9.77Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.